10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
22 line items · 2 periods
XBRL
| Item | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 4,584,100 | 5,881,217 |
Prepaid expenses and other current assets | 218,848 | 299,666 |
Total Current Assets | 4,802,948 | 6,180,883 |
Intangible assets, net | 2,643 | 2,784 |
Equity method investment | 421,730 | 489,700 |
Equity Method Investments | 421,730 | 489,700 |
Total Assets | 5,227,321 | 6,673,367 |
Current Liabilities: | ||
Accounts payable | 573,567 | 655,207 |
Accrued expenses | 936,504 | 741,702 |
Total Current Liabilities | 1,510,071 | 1,396,909 |
Total Liabilities | 1,510,071 | 1,396,909 |
Stockholders’ Equity | ||
Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 1,509,200 and 1,111,010 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 1,509 | 1,111 |
Additional paid in capital | 95,710,627 | 95,247,841 |
Accumulated deficit | (91,994,886) | (89,972,494) |
Total Stockholders’ Equity | 3,717,250 | 5,276,458 |
Common Stock | 1,509 | 1,111 |
Accumulated Deficit | (91,994,886) | (89,972,494) |
Additional Paid In Capital | 95,710,627 | 95,247,841 |
Total Liabilities and Stockholders’ Equity | 5,227,321 | 6,673,367 |